Entera Bio Ltd (NASDAQ: ENTX) announced a $275 million private placement that caused its shares to jump 44.5 percent on the day of the announcement. The financing, led by existing investor BVF Partners L.P., was oversubscribed and attracted new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital and Catalio Capital Management.
Under the securities purchase agreement, Entera will issue 122,961,215 ordinary shares at a price of $2.04 per share. In addition, the company will issue pre‑funded warrants that allow the purchase of up to 11,842,695 ordinary shares at the same $2.04 price. The warrants are immediately exercisable, carry no expiration date and have an exercise price of NIS 0.0000769 per share.
The private placement was priced at market in accordance with Nasdaq rules and is expected to close on or about July 28, 2026, subject to customary closing conditions. Entera stated that the net proceeds, when combined with its existing cash and cash equivalents, are expected to extend the company’s cash runway into 2030. The capital will fully fund Phase 3 registrational studies for EB613, an oral PTH(1‑34) peptide tablet being developed for osteoporosis treatment, and will also advance EB612, an oral PTH(1‑34) replacement therapy candidate, into Phase 1 development in collaboration with OPKO Health for hypoparathyroidism treatment.
As part of the agreement, BVF Partners will receive the right to designate two directors to Entera’s board, subject to applicable legal and Nasdaq requirements. Leerink Partners is serving as the lead placement agent, with Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital and Canaccord Genuity acting as co‑placement agents. The securities are being offered in a private placement and have not been registered under the Securities Act of 1933.